Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.29021/spdv.76.3.926 |
Resumo: | Vemurafenib, a selective inhibitor of the BRAF V600 mutation, is Food and Drug Administration and European Medicines Agency approved for the treatment of stage IV metastatic melanoma alone or in combination. Among the adverse effects, cutaneous toxicity is the most common. Most of these reactions such as maculopapular rash, photosensitivity and hyperkeratotic lesions are manageable, and the majority of patients are able to continue therapy. However, a few cases of life-threatening severe cutaneous adverse reactions have been reported and drug withdrawal is mandatory in these cases. Herein, we report a case of vemurafenib- -induced toxic epidermal necrolysis in a patient receiving therapy for metastatic melanoma. After several hospital complications, our patient survived to the drug-induced reaction and he is in remission for 2 years. |
id |
RCAP_4c0b8e56618a23ffffdcfbc93ffbcdd4 |
---|---|
oai_identifier_str |
oai:ojs.revista.spdv.com.pt:article/926 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse EventNecrólise Epidérmica Tóxica Induzida pelo Vemurafenib: Um Efeito Adverso EmergenteAntineoplastic Agents/adverse effectsMelanoma/drug therapyStevens-Johnson Syndrome/etiologyVemurafenibAntineoplásicos/efeitos adversosMelanoma/tratamentoSíndrome de Stevens-Johnson/etiologiaVemurafenibVemurafenib, a selective inhibitor of the BRAF V600 mutation, is Food and Drug Administration and European Medicines Agency approved for the treatment of stage IV metastatic melanoma alone or in combination. Among the adverse effects, cutaneous toxicity is the most common. Most of these reactions such as maculopapular rash, photosensitivity and hyperkeratotic lesions are manageable, and the majority of patients are able to continue therapy. However, a few cases of life-threatening severe cutaneous adverse reactions have been reported and drug withdrawal is mandatory in these cases. Herein, we report a case of vemurafenib- -induced toxic epidermal necrolysis in a patient receiving therapy for metastatic melanoma. After several hospital complications, our patient survived to the drug-induced reaction and he is in remission for 2 years.O vemurafenib, um inibidor seletivo da mutação BRAF V600, está aprovado pela Food and Drug Administration (FDA) e European Medicines Agency (EMA) para o tratamento de melanoma metastático em estadio IV isoladamente ou em combinação. De entre os efeitos adversos, a toxicidade cutânea é a mais comum. A maior parte destas reações, como o eritema, a fotossensibilidade e as lesões hiperqueratósicas, são facilmente controladas podendo a maioria dos doentes continuar terapêutica. Contudo, têm sido descritos alguns casos de reações cutâneas graves com risco de vida e necessidade de suspensão terapêutica. Os autores reportam um caso de necrólise epidérmica tóxica induzida pelo vemurafenib num doente a efetuar tratamento para melanoma metastizado. Após várias complicações hospitalares, o doente sobreviveu à reação provocada pelo fármaco e encontra-se em remissão há 2 anos.Sociedade Portuguesa de Dermatologia e Venereologia2018-10-05T00:00:00Zjournal articleinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://doi.org/10.29021/spdv.76.3.926oai:ojs.revista.spdv.com.pt:article/926Journal of the Portuguese Society of Dermatology and Venereology; Vol 76 No 3 (2018): July - September; 329-332Revista da Sociedade Portuguesa de Dermatologia e Venereologia; v. 76 n. 3 (2018): Julho - Setembro; 329-3322182-24092182-2395reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://revista.spdv.com.pt/index.php/spdv/article/view/926https://doi.org/10.29021/spdv.76.3.926https://revista.spdv.com.pt/index.php/spdv/article/view/926/591Monteiro, Ana FilipeRato, MargaridaMartins, Césarinfo:eu-repo/semantics/openAccess2022-10-06T12:35:08Zoai:ojs.revista.spdv.com.pt:article/926Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:11:07.279847Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event Necrólise Epidérmica Tóxica Induzida pelo Vemurafenib: Um Efeito Adverso Emergente |
title |
Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event |
spellingShingle |
Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event Monteiro, Ana Filipe Antineoplastic Agents/adverse effects Melanoma/drug therapy Stevens-Johnson Syndrome/etiology Vemurafenib Antineoplásicos/efeitos adversos Melanoma/tratamento Síndrome de Stevens-Johnson/etiologia Vemurafenib |
title_short |
Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event |
title_full |
Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event |
title_fullStr |
Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event |
title_full_unstemmed |
Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event |
title_sort |
Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event |
author |
Monteiro, Ana Filipe |
author_facet |
Monteiro, Ana Filipe Rato, Margarida Martins, César |
author_role |
author |
author2 |
Rato, Margarida Martins, César |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Monteiro, Ana Filipe Rato, Margarida Martins, César |
dc.subject.por.fl_str_mv |
Antineoplastic Agents/adverse effects Melanoma/drug therapy Stevens-Johnson Syndrome/etiology Vemurafenib Antineoplásicos/efeitos adversos Melanoma/tratamento Síndrome de Stevens-Johnson/etiologia Vemurafenib |
topic |
Antineoplastic Agents/adverse effects Melanoma/drug therapy Stevens-Johnson Syndrome/etiology Vemurafenib Antineoplásicos/efeitos adversos Melanoma/tratamento Síndrome de Stevens-Johnson/etiologia Vemurafenib |
description |
Vemurafenib, a selective inhibitor of the BRAF V600 mutation, is Food and Drug Administration and European Medicines Agency approved for the treatment of stage IV metastatic melanoma alone or in combination. Among the adverse effects, cutaneous toxicity is the most common. Most of these reactions such as maculopapular rash, photosensitivity and hyperkeratotic lesions are manageable, and the majority of patients are able to continue therapy. However, a few cases of life-threatening severe cutaneous adverse reactions have been reported and drug withdrawal is mandatory in these cases. Herein, we report a case of vemurafenib- -induced toxic epidermal necrolysis in a patient receiving therapy for metastatic melanoma. After several hospital complications, our patient survived to the drug-induced reaction and he is in remission for 2 years. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-10-05T00:00:00Z |
dc.type.driver.fl_str_mv |
journal article info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.29021/spdv.76.3.926 oai:ojs.revista.spdv.com.pt:article/926 |
url |
https://doi.org/10.29021/spdv.76.3.926 |
identifier_str_mv |
oai:ojs.revista.spdv.com.pt:article/926 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://revista.spdv.com.pt/index.php/spdv/article/view/926 https://doi.org/10.29021/spdv.76.3.926 https://revista.spdv.com.pt/index.php/spdv/article/view/926/591 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Dermatologia e Venereologia |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Dermatologia e Venereologia |
dc.source.none.fl_str_mv |
Journal of the Portuguese Society of Dermatology and Venereology; Vol 76 No 3 (2018): July - September; 329-332 Revista da Sociedade Portuguesa de Dermatologia e Venereologia; v. 76 n. 3 (2018): Julho - Setembro; 329-332 2182-2409 2182-2395 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130566848675840 |